JPH1124010A - Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agent - Google Patents
Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agentInfo
- Publication number
- JPH1124010A JPH1124010A JP9172529A JP17252997A JPH1124010A JP H1124010 A JPH1124010 A JP H1124010A JP 9172529 A JP9172529 A JP 9172529A JP 17252997 A JP17252997 A JP 17252997A JP H1124010 A JPH1124010 A JP H1124010A
- Authority
- JP
- Japan
- Prior art keywords
- contact lens
- drug
- sustained
- extended
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Compositions Of Macromolecular Compounds (AREA)
- Eyeglasses (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、薬剤徐放性視力矯
正用コンタクトレンズの製法およびそれに用いる薬剤徐
放剤に関する。さらに詳しくは、徐放剤である薬剤溶液
の微粉末やゲルを視力矯正用コンタクトレンズに付着さ
せ、該コンタクトレンズに薬剤徐放性を付与する方法お
よびそれに用いる薬剤徐放剤に関する。[0001] The present invention relates to a method for producing a contact lens for drug-controlled visual acuity correction and a drug sustained-release agent used therefor. More specifically, the present invention relates to a method for attaching a fine powder or gel of a drug solution as a sustained-release agent to a contact lens for vision correction to impart sustained drug release to the contact lens, and a drug sustained-release agent used for the method.
【０００２】[0002]
【従来の技術】従来、所望の薬剤徐放性が付与されたコ
ンタクトレンズとして、たとえば涙液に徐々に可溶な材
料を用いて形成したコンタクトレンズ中に薬剤を含有さ
せ、さらにその凸表面に涙液に難溶〜不溶な層を形成さ
せたコンタクトレンズ形状の角膜疾患治療具（実公昭５
７−２７４５７号公報）や、薬物を含有した持効性ポリ
マーヒドロゲル剤形を所望の形状に成形してなるコンタ
クトレンズ（特開昭６２−１０３０２９号公報）などが
提案されている。2. Description of the Related Art Conventionally, as a contact lens provided with a desired drug sustained release property, for example, a drug is contained in a contact lens formed using a material that is gradually soluble in tears, and a convex surface is formed on the contact lens. A corneal disease treatment device in the form of a contact lens in which a layer that is hardly soluble or insoluble in tears is formed.
No. 7-27457), and a contact lens formed by molding a long-acting polymer hydrogel formulation containing a drug into a desired shape (Japanese Patent Application Laid-Open No. 62-103029).
【０００３】しかしながら、前記コンタクトレンズ形状
の角膜疾患治療具を製造するには、薬剤を含有させる材
料として、たとえばセルロース、デンプン、ポリビニル
ピロリドン、アルギン酸ナトリウムなどの特定の化合物
を用いなければならないため、ごく一般的に通常コンタ
クトレンズに用いられるポリマーから、かかるコンタク
トレンズ形状の角膜疾患治療具を製造することはできな
い。However, in order to manufacture the contact lens-shaped therapeutic device for corneal diseases, specific compounds such as cellulose, starch, polyvinylpyrrolidone, and sodium alginate must be used as a material containing a drug. Generally, such a contact lens-shaped therapeutic device for corneal disease cannot be produced from a polymer generally used for a contact lens.
【０００４】また、前記コンタクトレンズをうる際の特
効性ポリマーヒドロゲル剤形用のポリマーは、すべての
タイプの架橋性化合物によって架橋されるものであるた
め、やはり通常コンタクトレンズに用いられるポリマー
がいずれも使用可能というわけではない。[0004] In addition, the polymer for the specific effect hydrogel formulation for producing the contact lens is crosslinked by all types of crosslinkable compounds. It is not usable.
【０００５】このように、その材質は従来より使用され
ている通常のものであり、しかもこれに充分な時間持続
しうる薬剤徐放性が付与されたコンタクトレンズがえら
れていないのが実情であり、このようなコンタクトレン
ズを製造する方法の開発が待ち望まれている。[0005] As described above, the material is a conventional one which has been used in the past, and there is no contact lens provided with the sustained release of the drug which can be maintained for a sufficient time. Therefore, development of a method for manufacturing such a contact lens has been awaited.
【０００６】[0006]
【発明が解決しようとする課題】本発明は、前記従来技
術に鑑みてなされたものであり、その材質にかかわら
ず、充分な時間持続しうる薬剤徐放性が付与されたコン
タクトレンズを、安価でかつ容易に製造する方法を提供
することを目的とする。DISCLOSURE OF THE INVENTION The present invention has been made in view of the above-mentioned prior art, and is intended to provide a contact lens provided with a sustained drug release which can be maintained for a sufficient time regardless of its material, at a low cost. It is an object of the present invention to provide a simple and easy manufacturing method.
【０００７】[0007]
【課題を解決するための手段】本発明は、 ポリヒドロキシアルキル（メタ）アクリレート、ポリ
ビニルピロリドン、ポリジメチルアクリルアミドおよび
ヒアルロン酸ナトリウムから選ばれた少なくとも１種の
ポリマーから微粉末状またはゲル状の薬剤徐放剤を調製
し、前記薬剤徐放剤をコンタクトレンズの一部に付着さ
せることを特徴とする薬剤徐放性視力矯正用コンタクト
レンズの製法、ならびに ポリヒドロキシアルキル（メタ）アクリレート、ポリ
ビニルピロリドン、ポリジメチルアクリルアミドおよび
ヒアルロン酸ナトリウムから選ばれた少なくとも１種の
ポリマーを薬剤の水溶液に溶解させてなる前記製法に用
いる微粉末状またはゲル状の薬剤徐放剤に関する。SUMMARY OF THE INVENTION The present invention relates to a method for preparing a fine powder or gel of a drug from at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate. A method of preparing a contact lens for drug-controlled visual acuity correction, comprising preparing a drug release and adhering the drug sustained-release agent to a part of the contact lens; and a polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, The present invention relates to a fine powder or gel drug sustained-release agent used in the above-mentioned production method, wherein at least one polymer selected from dimethylacrylamide and sodium hyaluronate is dissolved in an aqueous solution of the drug.
【０００８】[0008]
【発明の実施の形態】本発明の薬剤徐放性視力矯正用コ
ンタクトレンズの製法は、前記したように、ポリヒドロ
キシアルキル（メタ）アクリレート、ポリビニルピロリ
ドン、ポリジメチルアクリルアミドおよびヒアルロン酸
ナトリウムから選ばれた少なくとも１種のポリマーから
微粉末状またはゲル状の薬剤徐放剤を調製し、該薬剤徐
放剤をコンタクトレンズの一部に付着させることを特徴
とするものである。BEST MODE FOR CARRYING OUT THE INVENTION As described above, a method for producing a contact lens for sustained-release visual acuity correction of the present invention is selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate. A fine powder or gel drug sustained-release agent is prepared from at least one polymer, and the drug sustained-release agent is attached to a part of a contact lens.
【０００９】本発明では、コンタクトレンズに薬剤徐放
性を付与しうる薬剤徐放剤を、コンタクトレンズの一部
に付着させるので、従来のコンタクトレンズ材料そのも
のが薬剤を含有したものとは異なり、その材質にかかわ
らず、充分な時間持続しうる薬剤徐放性が付与されたコ
ンタクトレンズが容易にえられる。しかも用いる薬剤徐
放剤は、たとえば所望の薬剤の水溶液にポリヒドロキシ
アルキル（メタ）アクリレートなどのポリマーを溶解さ
せてえられるものであるので、安価であるという利点が
ある。In the present invention, since a drug sustained-release agent capable of imparting a drug sustained-release property to a contact lens is attached to a part of the contact lens, unlike a conventional contact lens material itself containing a drug, Regardless of the material, a contact lens provided with a sustained release of a drug that can be maintained for a sufficient time can be easily obtained. In addition, the drug sustained-release agent used is obtained by dissolving a polymer such as polyhydroxyalkyl (meth) acrylate in an aqueous solution of a desired drug, and thus has the advantage of being inexpensive.
【００１０】本発明の製法において、まず薬剤徐放剤を
調製する。In the production method of the present invention, first, a sustained-release drug is prepared.
【００１１】前記薬剤徐放剤は、たとえば、ポリヒドロ
キシアルキル（メタ）アクリレート、ポリビニルピロリ
ドン、ポリジメチルアクリルアミドおよびヒアルロン酸
ナトリウムから選ばれた少なくとも１種のポリマーを薬
剤の水溶液に溶解させることによってえられる。[0011] The drug sustained-release agent is obtained, for example, by dissolving at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate in an aqueous drug solution. .
【００１２】前記ポリマーのなかで、ポリヒドロキシア
ルキル（メタ）アクリレートの代表例としては、たとえ
ばポリヒドロキシエチル（メタ）アクリレート、ポリヒ
ドロキシプロピル（メタ）アクリレートなどがあげられ
る。Among the above-mentioned polymers, typical examples of polyhydroxyalkyl (meth) acrylate include polyhydroxyethyl (meth) acrylate, polyhydroxypropyl (meth) acrylate and the like.
【００１３】なお、本明細書において、「〜（メタ）ア
クリ・・・」とは、「〜アクリ・・・および／または〜
メタクリ・・・」を意味する。In this specification, "~ (meth) acryl ..." means "~ acryl ... and / or ...
Methacrylate ... ".
【００１４】本発明においては、種々の薬剤の水溶液に
対する溶解性がより高く、所望の薬剤徐放剤を調製しや
すいという点から、前記ポリマーのなかでも、ポリビニ
ルピロリドンおよびヒアルロン酸ナトリウムがとくに好
ましい。In the present invention, polyvinylpyrrolidone and sodium hyaluronate are particularly preferred among the above-mentioned polymers, because the solubility of various drugs in an aqueous solution is higher and a desired drug sustained-release agent can be easily prepared.
【００１５】また、前記ポリマーの重量平均分子量は、
最終的にえられるコンタクトレンズの装用感が充分に向
上するようにするためには、１００００以上、好ましく
は２００００以上であることが望ましく、またコンタク
トレンズがすぐれた薬剤徐放性を発現するようにするた
めには、２００００００以下、好ましくは１０００００
０以下であることが望ましい。Further, the weight average molecular weight of the polymer is:
In order to sufficiently improve the feeling of wearing the finally obtained contact lens, it is desirable that the contact lens has a molecular weight of 10,000 or more, preferably 20,000 or more. In order to achieve this, no more than 2,000,000, preferably 100,000
It is desirably 0 or less.
【００１６】前記薬剤としては、その水溶液が前記ポリ
マーを溶解しうるものであればよく、たとえば特開平８
−１０４６３０号公報、特公昭５９−７６８４号公報、
特表平７−５０３９７４号公報などに記載された、たと
えば炎症などの眼疾患や創傷などの予防剤や治療剤、診
断用剤、免疫抑制剤などの一般的な眼科用薬剤で、点眼
薬やその有効成分一般を用いることができる。かかる薬
剤の具体例としては、たとえば涙液増加剤、細胞増殖促
進剤、角膜厚の増加抑制剤、散瞳剤、縮瞳剤、抗生物質
製剤、抗菌剤、抗ヒスタミン剤、抗炎症剤、抗コリン
剤、抗緑内障化合物、抗ウイルス剤、炭酸脱水酵素阻害
剤、抗真菌剤、麻酔剤、ペプチド、タンパク質などがあ
げられる。The agent may be any agent as long as its aqueous solution can dissolve the polymer.
-104630, JP-B-59-7684,
General ophthalmic drugs such as preventive and therapeutic agents for eye diseases such as inflammation and wounds, diagnostic agents, immunosuppressants, and the like described in JP-T-7-503974 and the like. The general active ingredient can be used. Specific examples of such agents include, for example, tear-increasing agents, cell growth promoters, corneal thickness increase inhibitors, mydriatics, miotics, antibiotics, antibacterials, antihistamines, anti-inflammatory agents, anticholinergic agents And anti-glaucoma compounds, anti-viral agents, carbonic anhydrase inhibitors, anti-fungal agents, anesthetics, peptides, proteins and the like.
【００１７】薬剤の水溶液にポリマーを溶解させて溶液
をうる際の該薬剤とポリマーとの割合は、用いたこれら
薬剤およびポリマーの種類などに応じ、均一な溶液がえ
られるように適宜調整すればよく、とくに限定がない
が、たとえば溶液の濃度が０．５〜１０ｗ／ｖ％程度と
なるようにすることが好ましい。The ratio between the drug and the polymer when the solution is obtained by dissolving the polymer in the aqueous solution of the drug may be appropriately adjusted according to the type of the drug and the polymer used so as to obtain a uniform solution. Although there is no particular limitation, it is preferable that the concentration of the solution is, for example, about 0.5 to 10 w / v%.
【００１８】また、前記溶液の回転粘度計にて測定した
２０℃での粘度は、最終的にえられるコンタクトレンズ
の装用感が充分に向上するようにするためには、１Ｐ以
上、好ましくは２Ｐ以上であることが望ましく、またコ
ンタクトレンズがすぐれた薬剤徐放性を発現するように
するためには、１００Ｐ以下、好ましくは９０Ｐ以下で
あることが望ましい。The viscosity of the solution at 20 ° C. measured by a rotational viscometer should be 1 P or more, preferably 2 P, in order to sufficiently improve the wearing feeling of the contact lens finally obtained. It is preferably at least 100P, and more preferably at most 100P, preferably at most 90P, in order for the contact lens to exhibit excellent drug sustained release.
【００１９】前記のごとくえられた溶液から本発明の微
粉末状またはゲル状の薬剤徐放剤を調製するには、たと
えば該溶液を減圧下で噴霧し、乾燥粉末化させるスプレ
ードライ法によって微粉末状とする方法などを採用する
ことができる。In order to prepare the fine powdered or gelled sustained-release drug of the present invention from the solution obtained as described above, for example, the solution is sprayed under reduced pressure to form a fine powder by a spray-drying method. A method of forming a powder can be employed.
【００２０】なお、本発明の薬剤徐放剤が微粉末状また
はゲル状であるのは、かかる薬剤徐放剤がコンタクトレ
ンズに付着しやすくなるようにするためである。また、
該薬剤徐放剤が微粉末状であるばあい、その平均粒子径
は１５μｍ程度以下であることが好ましく、そのなかで
も、粒径が３μｍ程度以下の微粒子を用いることがとく
に好ましい。ただし、コンタクトレンズが非含水性のも
のであるばあいには、薬剤徐放剤を付着させる際のレン
ズの固定が困難であるため、微粉末状でなく、ゲル状の
薬剤徐放剤が通常用いられる。The drug sustained-release agent of the present invention is in the form of a fine powder or a gel so that the drug sustained-release agent can easily adhere to a contact lens. Also,
When the drug sustained release agent is in the form of a fine powder, the average particle size is preferably about 15 μm or less, and among them, it is particularly preferable to use fine particles having a particle size of about 3 μm or less. However, if the contact lens is non-hydrous, it is difficult to fix the lens when attaching the drug sustained-release agent. Used.
【００２１】つぎに、かくしてえられた薬剤徐放剤をコ
ンタクトレンズの一部に付着させることにより、薬剤徐
放性視力矯正用コンタクトレンズがえられる。Next, the drug sustained-release agent thus obtained is adhered to a part of the contact lens to obtain a drug sustained-release vision-correcting contact lens.
【００２２】本発明において、薬剤徐放性を付着させる
部位は、コンタクトレンズを装用した際に視界を遮らな
いようなレンズ光学領域以外であるかぎり、とくに限定
がないが、装用感がより向上するという点から、レンズ
周辺部に付着させることが好ましい。In the present invention, there is no particular limitation on the part to which the sustained release of the drug is adhered, as long as it is outside the lens optical region where the field of view is not obstructed when the contact lens is worn, but the feeling of wearing is further improved. From this point, it is preferable that the adhesive be attached to the peripheral portion of the lens.
【００２３】薬剤徐放剤をコンタクトレンズの一部に付
着させるには、たとえば薬剤徐放剤をコンタクトレンズ
に直接塗布したり、押当てたり、吹付けたりするほか、
薬剤徐放剤にコンタクトレンズを浸漬させたりする方法
を採用することができる。In order to adhere the drug sustained-release agent to a part of the contact lens, for example, the drug sustained-release agent is directly applied to the contact lens, pressed or sprayed,
A method in which a contact lens is immersed in a drug sustained-release agent can be adopted.
【００２４】また、薬剤徐放剤のコンタクトレンズにお
ける付着量は、薬剤徐放性が充分に発現されるような量
であればよく、とくに限定がないが、コンタクトレンズ
の装用の妨げとならないようにするために、たとえばコ
ンタクトレンズ１枚あたり２０ｍｇ程度以下となるよう
に調整すればよい。[0024] The amount of the drug sustained-release agent adhered to the contact lens is not particularly limited as long as the drug sustained release property is sufficiently exhibited, and is not particularly limited. In order to achieve this, the adjustment may be made, for example, so as to be about 20 mg or less per contact lens.
【００２５】なお、本発明において、薬剤徐放剤を付着
させるコンタクトレンズにはとくに限定がなく、たとえ
ば通常コンタクトレンズをうる際に用いられるシリコン
含有モノマー、フッ素含有モノマー、水酸基含有モノマ
ー、架橋性モノマーなどの各種モノマーを用いて通常の
方法で製造されたコンタクトレンズを、例外なく用いる
ことができる。In the present invention, the contact lens to which the sustained-release agent is adhered is not particularly limited. For example, a silicon-containing monomer, a fluorine-containing monomer, a hydroxyl-containing monomer, and a cross-linkable monomer which are usually used when obtaining a contact lens Contact lenses manufactured by a usual method using various monomers such as the above can be used without exception.
【００２６】かくして本発明の製法によってえられる薬
剤徐放性視力矯正用コンタクトレンズは、その一部に付
着した薬剤徐放剤から薬剤が充分な時間にわたって徐放
するものであるので、各種予防、治療、診断、免疫抑制
などの眼科用コンタクトレンズとして好適に用いること
ができる。Thus, the contact lens for sustained-release visual acuity correction obtained by the production method of the present invention is one in which the drug is gradually released from the sustained-release agent adhered to a part of the contact lens over a sufficient period of time. It can be suitably used as an ophthalmic contact lens for treatment, diagnosis, immunosuppression and the like.
【００２７】[0027]
【実施例】つぎに、本発明の薬剤徐放性視力矯正用コン
タクトレンズの製法およびそれに用いる薬剤徐放剤を実
施例に基づいてさらに詳細に説明するが、本発明はかか
る実施例のみに限定されるものではない。Next, the method for producing the contact lens for sustained-release visual acuity correction according to the present invention and the sustained-release agent for use therein will be described in more detail with reference to Examples, but the present invention is limited to only these Examples. It is not something to be done.
【００２８】実施例１ 点眼液である１％塩酸カルテオロール水溶液１２ｍｌ
に、ポリビニルピロリドン（重量平均分子量：８０００
０）６００ｍｇを溶解させて５ｗ／ｖ％溶液をえた。か
かる溶液の２０℃での粘度は５Ｐであった。Example 1 12 ml of a 1% aqueous carteolol hydrochloride solution as an ophthalmic solution
To polyvinylpyrrolidone (weight average molecular weight: 8000
0) 600 mg was dissolved to obtain a 5% w / v solution. The viscosity of the solution at 20 ° C. was 5P.
【００２９】つぎに、前記溶液からスプレードライ法に
よって平均粒子径が１０μｍ程度の微粉末状の薬剤徐放
剤を調製した。こののち、空気を吹き上げて粒径が３μ
ｍ以下の微粒子のみを分級した。Next, a fine powdery sustained-release agent having an average particle diameter of about 10 μm was prepared from the above solution by a spray drying method. After that, air is blown up and the particle size becomes 3μ.
Only the fine particles of m or less were classified.
【００３０】さらに、（株）メニコン製のソフトコンタ
クトレンズ「メニコンソフトＭＡ」（商品名）のレンズ
外周の一部に、抽出した粒径が３μｍ以下の微粒子約１
ｍｇを手指にて塗布して付着させた。付着した微粒子は
速やかに吸水し、ゲル状となった。Further, a part of the extracted microparticles having a particle diameter of 3 μm or less is partially added to a part of the outer periphery of a soft contact lens “MENICON SOFT MA” (trade name) manufactured by Menicon Corporation.
mg was manually applied and adhered. The attached fine particles quickly absorbed water and became a gel.
【００３１】前記微粒子が付着したコンタクトレンズを
家兎眼に装用させ、３６時間経過後にその眼圧を測定し
たところ、眼圧は装用前より低下しており、徐放性が長
時間にわたって持続していた。The contact lens to which the fine particles were attached was worn on rabbit eyes, and its intraocular pressure was measured 36 hours later. The intraocular pressure was lower than before wearing, and the sustained release was maintained for a long time. I was
【００３２】実施例２ 点眼液である１％塩酸カルテオロール水溶液８ｍｌに、
ヒアルロン酸ナトリウム（重量平均分子量：８００００
０）８０ｍｇを溶解させてゲル状の１ｗ／ｖ％溶液をえ
た。かかる溶液の２０℃での粘度は１０Ｐであった。Example 2 Into 8 ml of a 1% aqueous solution of carteolol hydrochloride as an ophthalmic solution,
Sodium hyaluronate (weight average molecular weight: 80000)
0) 80 mg was dissolved to obtain a gel-like 1 w / v% solution. The viscosity at 20 ° C. of the solution was 10P.
【００３３】つぎに、一方の端部（底面）に孔径が１０
μｍのナイロンメッシュを配置した円筒形容器内に前記
溶液を入れた。Next, one end (bottom surface) has a hole diameter of 10 mm.
The solution was placed in a cylindrical container having a nylon mesh of μm.
【００３４】さらに、（株）メニコン製のコンタクトレ
ンズ「メニコンＥＸ」（商品名）のレンズ外周全体に、
前記円筒形容器から溶液（ゲル状の薬剤徐放剤）約１０
ｍｇを押出して付着させた。Further, a contact lens “MENICON EX” (trade name) manufactured by Menicon Co., Ltd.
Approximately 10 solutions (gel release agent) from the cylindrical container
mg was extruded and deposited.
【００３５】前記ゲル状の薬剤徐放剤が付着したコンタ
クトレンズを家兎眼に装用させ、３６時間経過後にその
眼圧を測定したところ、眼圧は装用前より低下してお
り、徐放性が長時間にわたって持続していた。The contact lens to which the gel-like drug sustained-release agent was attached was worn on rabbit eyes, and its intraocular pressure was measured after 36 hours. For a long time.
【００３６】[0036]
【発明の効果】本発明の製法によれば、その材質にかか
わらず、充分な時間持続しうる薬剤徐放性が付与され、
しかも装用感が向上した薬剤徐放性視力矯正用コンタク
トレンズを容易に製造することができる。According to the production method of the present invention, a sustained drug release that can be maintained for a sufficient time is imparted regardless of its material,
In addition, it is possible to easily produce a contact lens for drug sustained release eyesight correction with improved wearing feeling.
【００３７】したがって、前記製法によってえられる薬
剤徐放性視力矯正用コンタクトレンズは、各種予防、治
療、診断、免疫抑制などの眼科用コンタクトレンズとし
て好適に用いることができる。Therefore, the contact lens for sustained-release visual acuity correction obtained by the above-mentioned manufacturing method can be suitably used as an ophthalmic contact lens for various prevention, treatment, diagnosis, immunosuppression and the like.
【００３８】また、前記製法に用いる薬剤徐放剤は、安
価であるという利点を有する。The sustained-release drug used in the above-mentioned production method has an advantage of being inexpensive.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ｃ０８Ｌ 39/06 Ｃ０８Ｌ 39/06 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI C08L 39/06 C08L 39/06
Claims (5)
レート、ポリビニルピロリドン、ポリジメチルアクリル
アミドおよびヒアルロン酸ナトリウムから選ばれた少な
くとも１種のポリマーから微粉末状またはゲル状の薬剤
徐放剤を調製し、前記薬剤徐放剤をコンタクトレンズの
一部に付着させることを特徴とする薬剤徐放性視力矯正
用コンタクトレンズの製法。1. A fine powder or gel drug sustained-release agent is prepared from at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate. A method for producing a drug sustained-release vision-correcting contact lens, characterized in that a sustained-release agent is attached to a part of the contact lens.
られた溶液から薬剤徐放剤を調製する請求項１記載の薬
剤徐放性視力矯正用コンタクトレンズの製法。2. The method according to claim 1, wherein the polymer is dissolved in an aqueous solution of a drug, and a sustained-release drug is prepared from the obtained solution.
〜２００００００である請求項１または２記載の薬剤徐
放性視力矯正用コンタクトレンズの製法。3. The weight average molecular weight of the polymer is 10,000.
3. The method for producing a drug sustained-release visual acuity correcting lens according to claim 1 or 2, which has a molecular weight of up to 2,000,000.
ある請求項２または３記載の薬剤徐放性視力矯正用コン
タクトレンズの製法。4. The method for producing a drug according to claim 2, wherein the solution has a viscosity at 20 ° C. of 1 to 100 P.
レート、ポリビニルピロリドン、ポリジメチルアクリル
アミドおよびヒアルロン酸ナトリウムから選ばれた少な
くとも１種のポリマーを薬剤の水溶液に溶解させてなる
請求項１、２、３または４記載の製法に用いる微粉末状
またはゲル状の薬剤徐放剤。5. The method according to claim 1, wherein at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate is dissolved in an aqueous solution of a drug. A sustained-release agent in the form of a fine powder or a gel used in the production method described above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9172529A JPH1124010A (en) | 1997-06-27 | 1997-06-27 | Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9172529A JPH1124010A (en) | 1997-06-27 | 1997-06-27 | Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1124010A true JPH1124010A (en) | 1999-01-29 |
Family
ID=15943616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9172529A Pending JPH1124010A (en) | 1997-06-27 | 1997-06-27 | Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1124010A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009154169A1 (en) | 2008-06-19 | 2009-12-23 | 学校法人近畿大学 | Peptide derivative and composition for promoting tear secretion comprising the same |
| JP2012005858A (en) * | 2004-07-02 | 2012-01-12 | Qlt Inc | Treatment medium delivery device and method for delivery of the treatment medium to eye using the delivery device |
| JP2017052911A (en) * | 2015-09-11 | 2017-03-16 | 株式会社日本触媒 | Gelatinizer for sustained release pharmaceuticals |
-
1997
- 1997-06-27 JP JP9172529A patent/JPH1124010A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012005858A (en) * | 2004-07-02 | 2012-01-12 | Qlt Inc | Treatment medium delivery device and method for delivery of the treatment medium to eye using the delivery device |
| JP2014176671A (en) * | 2004-07-02 | 2014-09-25 | Qlt Inc | Treatment medium delivery device, and methods for delivery of treatment mediums to eye using the delivery device |
| WO2009154169A1 (en) | 2008-06-19 | 2009-12-23 | 学校法人近畿大学 | Peptide derivative and composition for promoting tear secretion comprising the same |
| JP2017052911A (en) * | 2015-09-11 | 2017-03-16 | 株式会社日本触媒 | Gelatinizer for sustained release pharmaceuticals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5731005A (en) | Hydrogel-based microsphere drug delivery systems | |
| US5137728A (en) | Ophthalmic article | |
| Saettone et al. | Ocular inserts for topical delivery | |
| Kumar et al. | Ocular inserts: A novel controlled drug delivery system | |
| EP1164987A1 (en) | Improved conjunctival inserts for topical delivery of medication or lubrication | |
| TW201043211A (en) | Punctal plugs | |
| RU2749426C2 (en) | Non-invasive medicine delivery technique using eye inlay | |
| Karthikeyan et al. | The concept of ocular inserts as drug delivery systems: An overview | |
| Calles et al. | Polymers in ophthalmology | |
| Saettone | Solid polymeric inserts/disks as drug delivery devices | |
| WO1994010976A1 (en) | Polyvinyl alcohol/borate ophthalmic drug delivery system | |
| JPH09136902A (en) | Photo-crosslinking hyaluronic acid contact lens | |
| Jindal et al. | Hydrogels for localized drug delivery: a special emphasis on dermatologic applications | |
| Kumaran et al. | Comparative review on conventional and advanced ocular drug delivery formulations | |
| JPH1124010A (en) | Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agent | |
| Khan et al. | Ocular inserts-a novel approach in ocular drug delivery | |
| Felt et al. | Polymeric systems for ophthalmic drug delivery | |
| Khokhar et al. | Ocular drug Delivery system-a review based on ocuserts | |
| CN102198087B (en) | Preservative-free ophthalmic in-situ gelling agent and preparation method thereof | |
| Madhuri et al. | Ocular inserts: A rate controlled drug delivery system–a review | |
| Shastri et al. | Novel alternative to ocular drug delivery system: Hydrogel | |
| Chowhan et al. | Drug delivery-ophthalmic route | |
| Ara et al. | Occular Drug Delivery System: An Overview | |
| KR102612306B1 (en) | Manufacturing method contact lens for drug delivery | |
| Mundada | Update on Polymers for Ocular Drug Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040401 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071120 |